- Trials with a EudraCT protocol (356)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (35)
Query did not match any clinical trials.
| These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006). | |
| Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records. | |
| Study title: Presynaptic catecholamine antagonists as treatment for Tourette syndrome. Effects of alpha methyl para tyrosine and tetrabenazine. |
| Active substance: BENZATROPINE |
| Study summary document link (including results): |
| View full study record |
| Document reference: 22252 |
| Study title: Presynaptic catecholamine antagonists as treatment for Tourette syndrome. Effects of alpha methyl para tyrosine and tetrabenazine. |
| Active substance: BENZATROPINE |
| Study summary document link (including results): |
| View full study record |
| Document reference: 41956 |
| Study title: Six Week, Double-Blind, Safety Study of Beclomethasone Dipropionate Oral Aerosol vs. Placebo in Children (Less than 6 Years of Age) with a Clinical Diagnosis of Asthma or History/Active Wheezing and/or Usage of Beta-Agonists Compatible with the Diagnosis of Asthma |
| Active substance: BECLAMETHASONE |
| Study summary document link (including results): |
| View full study record |
| Document reference: 22239 |
| Study title: A randomised, double-blind, double-dummy, parallel-group, multicentre, phase-III study to investigate the effect of Symbicort® Turbuhaler® (budesonide/formoterol) 1280/36 µg total delivered dose in the treatment of acute asthma compared with Oxis® Turbuhaler® (formoterol) 36 µg total delivered dose in adolescent and adult patients not responding adequately to β2-agonists |
| Active substance: BUDESONIDE AND FORMOTEROL |
| Study summary document link (including results): D5896C00005 CSR Synopsis.pdf |
| View full study record |
| Document reference: 23043 |
| Study title: Meier CM et al 2007 British Journal of Clinical Pharmacology 2007;63(5):628. Palatability of angiotensin II antagonists among nephropathic children.Meier CM et al 2007 British Journal of Clinical Pharmacology 2007;63(5):628. Palatability of angiotensin II antagonists among nephropathic children. |
| Active substance: CANDESARTAN CILETEXIL |
| Study summary document link (including results): |
| View full study record |
| Document reference: 23217 |
| Study title: Meier CM et al. Palatability of angiotensin II antagonists among nephropathic children. British Journal of Clinical Pharmacology 2007;63(5):628.Meier CM et al. Palatability of angiotensin II antagonists among nephropathic children. British Journal of Clinical Pharmacology 2007;63(5):628. |
| Active substance: CANDESARTAN CILETEXIL |
| Study summary document link (including results): |
| View full study record |
| Document reference: 23213 |
| Study title: Palatability of angiotensin II antagonists among nephropathic children. Meier CM 2007Palatability of angiotensin II antagonists among nephropathic children. Meier CM 2007 |
| Active substance: CANDESARTAN CILETEXIL |
| Study summary document link (including results): |
| View full study record |
| Document reference: 23204 |
| Study title: Esperienza clinica con alpha−bloccanti e calcioantagonisti nel trattamento perioperatorio del feocromocitoma. (Clinical experience with alpha blockers and calcium antagonists in the perioperative treatment of pheochromocytoma). Furino A, Massagli C, Pesce CV, Vulpis V. Minerva anestesiologica, { Dec 1994, vol. 60, no. 12, p. 719−23Esperienza clinica con alpha−bloccanti e calcioantagonisti nel trattamento perioperatorio del feocromocitoma. (Clinical experience with alpha blockers and calcium antagonists in the perioperative treatment of pheochromocytoma). Furino A, Massagli C, Pesce CV, Vulpis V. Minerva anestesiologica, { Dec 1994, vol. 60, no. 12, p. 719−23 |
| Active substance: DILTIAZEM |
| Study summary document link (including results): |
| View full study record |
| Document reference: 26133 |
| Study title: Beta−adrenoblokatory i antagonisti kal'tsiia pri gipertroficheskoi kardiomiopatii. (Beta−adrenergic blockers and calcium antagonists in hypertrophic cardiomyopathy).Korovina EP. Klinicheskaia meditsina, 1998, vol. 76, no. 12, p. 30−5Beta−adrenoblokatory i antagonisti kal'tsiia pri gipertroficheskoi kardiomiopatii. (Beta−adrenergic blockers and calcium antagonists in hypertrophic cardiomyopathy).Korovina EP. Klinicheskaia meditsina, 1998, vol. 76, no. 12, p. 30−5 |
| Active substance: DILTIAZEM |
| Study summary document link (including results): |
| View full study record |
| Document reference: 26117 |
| Study title: Benefit/risk ratio of the antihistamines (H1-receptor antagonists) terfenadine and chlorpheniramine in children. |
| Active substance: CHLORPHENAMINE AND PARACETAMOL |
| Study summary document link (including results): |
| View full study record |
| Document reference: 24038 |
| Study title: bronchodilator effect of two inhaled H1-receptor antagonists, clemastine and chlorpheniramine, in wheezy school-children. |
| Active substance: CHLORPHENAMINE AND PARACETAMOL |
| Study summary document link (including results): |
| View full study record |
| Document reference: 24042 |
| Study title: Clinical pharmacology of the H1-receptor antagonists cetirizine and loratadine in children. |
| Active substance: CETIRIZINE |
| Study summary document link (including results): |
| View full study record |
| Document reference: 23718 |
| Study title: Benefit/risk ratio of the antihistamines (H1-receptor antagonists) terfenadine and chlorpheniramine in children. |
| Active substance: CHLORPHENAMINE AND TRAMAZOLINE |
| Study summary document link (including results): |
| View full study record |
| Document reference: 24058 |
| Study title: bronchodilator effect of two inhaled H1-receptor antagonists, clemastine and chlorpheniramine, in wheezy school-children. |
| Active substance: CHLORPHENAMINE AND TRAMAZOLINE |
| Study summary document link (including results): |
| View full study record |
| Document reference: 24059 |
| Study title: A multicenter, randomized, double-blind, placebo-controlled, parallel study of the efficacy and safety of chlorofluorocarbon (CFC) and HFA-227 (non-CFC) formulations of Intal® (cromolyn sodium) metered dose inhaler (MDI) 2mg Qid in the treatment of asthma in patients 12 years and older using PRN β2agonists administered by MDI - Dr M.N. Blumenthal et al. - 1995 to 1996 - Intal 1mg HFA-227, volume 4 Tabulated Study Reports - 2000 - |
| Active substance: CROMOGLICIC ACID |
| Study summary document link (including results): PNI 10402509.pdf |
| View full study record |
| Document reference: 24659 |
| Study title: A multicenter, randomized, double-blind, placebo-controlled, parallel study of the efficacy and safety of chlorofluorocarbon (CFC) and non-CFC formulations of Intal® (cromolyn sodium) metered dose inhaler (MDI) 2 mg QID in the treatment of asthma in patients 12 years and older using PRN β2 agonists administered by MDI |
| Active substance: CROMOGLICIC ACID |
| Study summary document link (including results): PNI 10402508.pdf |
| View full study record |
| Document reference: 24667 |
| Study title: McDonnell M, Evans N. Upper and lower gastrointestinal complications with dexamethasone despite H2 antagonists. J Paediatr Child Health 1995;31:152-154. |
| Active substance: DEXAMETHASONE |
| Study summary document link (including results): |
| View full study record |
| Document reference: 25687 |
| Study title: Placebo-Controlled Efficacy and Safety Study of a Once-Daily, PM Regimen of Mometasone Furoate (SCH 32088) Dry Powder in Asthmatics Previously Maintained on Short-acting Inhaled Beta-agonists |
| Active substance: MOMETAZONE |
| Study summary document link (including results): C98-475_mometasone furoates.pdf |
| View full study record |
| Document reference: 48179 |
| Study title: Albano MCC, Latronico AC, Arnhold IJP, Domenice S, Bloise W, Mendonca BB. Long-acting gonadotropin-releasing hormone agonists in the differential diagnosis of male precocious puberty. Journal of Pediatric Endocrinology and Metabolism 10(5)()(pp 499-503), 1997 Date of Publication: 1997 1997;(5):499-503.Albano MCC, Latronico AC, Arnhold IJP, Domenice S, Bloise W, Mendonca BB. Long-acting gonadotropin-releasing hormone agonists in the differential diagnosis of male precocious puberty. Journal of Pediatric Endocrinology and Metabolism 10(5)()(pp 499-503), 1997 Date of Publication: 1997 1997;(5):499-503. |
| Active substance: GOSERELIN |
| Study summary document link (including results): |
| View full study record |
| Document reference: 29000 |
| Study title: Breyer P, Haider A, Pescovitz O. Gonadotropin-releasing hormone agonists in the treatment of girls with central precocious puberty. Clinical Obstetrics and Gynecology 1993; 36(3):764-772.Breyer P, Haider A, Pescovitz O. Gonadotropin-releasing hormone agonists in the treatment of girls with central precocious puberty. Clinical Obstetrics and Gynecology 1993; 36(3):764-772. |
| Active substance: GOSERELIN |
| Study summary document link (including results): |
| View full study record |
| Document reference: 29004 |
